Seema Bhat

7PUBLICATIONS
93CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 14, 2026
Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22.

|Apr 22, 2026
Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib.

|Nov 05, 2025
PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor-Resistant Chronic Lymphocytic Leukemia.

Britten K Gordon, Elizabeth M Muhowski, Jyotsana Singh

|Dec 24, 2024
Non-V600E BRAF mutations and treatment for hairy cell leukemia.

Evgeny Arons, Chin-Hsien Tai, Joshi Suraj

|Nov 06, 2023
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma.

Jennifer A Woyach, Deborah M Stephens, Ian W Flinn

|May 24, 2022
Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study.

Deborah M Stephens, Ying Huang, Amy S Ruppert

Pageof 2

Frequent Collaborators

6 joint publications

Kerry Rogers

5 joint publications

Jennifer A Woyach

4 joint publications

John C Byrd

2 joint publications

Shanmugapriya Thangavadivel